GE HealthCare Technologies Inc. Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $21B+6.6% YoYTTM through 31 Mar 2026
Net Income $1.9B-4.2% YoYTTM through 31 Mar 2026
Free Cash Flow $1.5BTTM through 31 Mar 2026
Margins
| Current | |
|---|---|
| Gross Margin | 40.0% |
| EBITDA Margin | 15.4% |
| Operating Margin | 13.4% |
| Net Margin | 9.1% |
Returns
20.8%ROE
5.8%ROA
11.5%ROIC
Balance Sheet Health
Debt / Equity0.96x
Current Ratio1.37x
Net Debt$5.5B
Cash & Equivalents$2.3B
Quality Metrics
Altman Z-Score1.76
Piotroski F-Score5 / 9
FCF Margin7.0%
Rule of 4010.6
Earnings-Beat Rate75.0%
Multi-Year Trend
RevenueFY2025: $20.6B
Diluted EPS$4.17TTMFY2025: $4.55
Dividend
$0.07Per share, FY20260.23%Yield
Capital Allocation
R&D Spend$1.3B
Capex Intensity2.4%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Imaging | $9.2B | +4.4% | View detailsOrganic revenue growth of 3.0% to 4.0% year-over-year for 2026 |
| Advanced Visualization Solutions (AVS) | $5.4B | +4.3% | |
| Patient Care Solutions | $3.1B | -1.2% | |
| Pharmaceutical Diagnostics (PDx) | $2.9B | +15.6% | View detailsOrganic revenue growth of 3.0% to 4.0% year-over-year for 2026 |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.